Precision Pathways: Emerging Targeted Therapies in HR+/HER2- Breast Cancer
Panelists discuss how emerging targeted therapies, including novel PI3K inhibitors and combination treatments, are advancing precision pathways in HR positive (HR+)/HER2 negative (HER2-) breast cancer, offering new hope for personalized treatment and improved patient outcomes.
Now Viewing
EP: 1.Precision Pathways: Emerging Targeted Therapies in HR+/HER2- Breast Cancer
EP: 2.INAVO120 Trial Insights and Inavolisib's Emerging Role in the Treatment Armamentarium
EP: 3.Precision Pathways: Targeted Therapies, Mutation-Driven Treatment Strategies
EP: 4.Biomarker Testing Best Practices for Informed Treatment Decision-Making: Med Onc and Nurse Perspectives
EP: 5.Adapting Biomarker Testing Practices as Targeted Therapies Shift to Earlier Lines of Treatment
EP: 6.Hyperglycemia Monitoring and AIC Monitoring with PI3K/AKT Pathway Inhibitors: Practical Approaches and Strategies
EP: 7.Treatment Decision-Making in PIK3CA-mut HR+/HER2- Breast Cancer: Key Tolerability Considerations
EP: 8.Strategies for Staying Informed and Coordinating Care as New Agents Emerge in HR+/HER2- Breast Cancer
EP: 9.PI3K Inhibitors, Oral SERDs, Combination Therapies, and the Shifting Treatment Landscape
Recent Videos
Related Content
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Podcast
Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
